Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence polarization-based biochemical dose-response assay for inhibitors of wild-type (WT) recombinant IDE (ROUND 2)
Assay data:3 Active, 26 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence-based IDE activity assay using a fluorogenic peptide substrate (FRET1) to identify fluorescent artifacts (ROUND2)
Assay data:1 Active, 26 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same Project
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence-based cysteine-free mutant IDE activity assay using a fluorogenic peptide substrate (FRET1) (reversibility) (Round 2)
Assay data:26 Tested
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence-based cysteine-free mutant IDE activity assay using a fluorogenic peptide substrate (FRET1) (reversibility)
Assay data:2 Active, 13 Tested
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence polarization-based biochemical dose-response assay for inhibitors of wild-type (WT) recombinant IDE
Assay data:6 Active, 8 Tested
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence-based IDE activity assay using a fluorogenic peptide substrate (FRET1) to identify fluorescent artifacts
Assay data:10 Active, 2 Activity ≤ 1 µM, 55 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same Project
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: TR-FRET-based IDE activity assay to identify inhibitors of recombinant IDE's degradation of insulin
Assay data:3 Active, 17 Tested
Late stage counterscreen assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): fluorescence polarization-based biochemical dose response assay to identify fluorescent artifacts and/or optically active compounds
Assay data:1 Active, 32 Tested
Late stage assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): Fluorescence polarization-based cell-based dose response assay for inhibitors of IDE
Assay data:7 Active, 32 Tested
Late stage counterscreen assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): Fluorescence polarization-based biochemical dose response assay for inhibitors of recombinant IDE
Assay data:9 Active, 32 Tested
Late stage counterscreen assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): Luminescence-based cell-based dose response assay to identify compounds that are cytotoxic to HEK cells
Assay data:2 Active, 32 Tested
Counterscreen for IDE inhibitors: Luminescence-based cell-based high throughput dose response assay to identify compounds that are cytotoxic to HEK cells
Assay data:1 Active, 1 Activity ≤ 1 µM, 127 Tested
Dose Response: Fluorescence polarization-based cell-based high throughput dose response assay for inhibitors of insulin-degrading enzyme (IDE)
Assay data:44 Active, 1 Activity ≤ 1 µM, 127 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Counterscreen for IDE inhibitors: Luminescence-based cell-based high throughput assay to identify cytotoxic compounds using HEK cells
Assay data:334 Active, 1179 Tested
Fluorescence polarization-based cell-based high throughput confirmation assay for inhibitors of insulin-degrading enzyme (IDE)
Assay data:598 Active, 1179 Tested
Summary of probe development efforts to identify inhibitors of insulin-degrading enzyme (IDE)
Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE)
Assay data:1316 Active, 324858 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on